A fast-moving entry in the gene editing race is speeding to the clinic, fueled by an $83.5M round
The last time I talked to Arthur Tzianabos a little more than a year ago, the CEO at Homology Medicines had a team of about 10 and a new approach to in vivo gene transfer and gene editing that was still in preclinical liftoff mode. Today, Tzianabos is whipping the cover off a whopping $83.5 million venture round with some A-lister support so his team of 40-plus can take their work into humans for the first time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
